Cargando…
A Role for Fibroblast Growth Factor 19 and Bile Acids in Diabetes Remission After Roux-en-Y Gastric Bypass
OBJECTIVE: Roux-en-Y gastric bypass (RYGB) in humans can remit type 2 diabetes, but the operative mechanism is not completely understood. In mice, fibroblast growth factor (FGF) 15 (FGF19 in humans) regulates hepatic bile acid (BA) production and can also resolve diabetes. In this study, we tested t...
Autores principales: | Gerhard, Glenn S., Styer, Amanda M., Wood, G. Craig, Roesch, Stephen L., Petrick, Anthony T., Gabrielsen, Jon, Strodel, William E., Still, Christopher D., Argyropoulos, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687273/ https://www.ncbi.nlm.nih.gov/pubmed/23801799 http://dx.doi.org/10.2337/dc12-2255 |
Ejemplares similares
-
Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery
por: Still, Christopher D., et al.
Publicado: (2014) -
Perturbations of Fibroblast Growth Factors 19 and 21 in Type 2 Diabetes
por: Roesch, Stephen L., et al.
Publicado: (2015) -
All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes
por: Lent, Michelle R., et al.
Publicado: (2017) -
A Patient-Centered Electronic Tool for Weight Loss Outcomes after Roux-en-Y Gastric Bypass
por: Wood, G. Craig, et al.
Publicado: (2014) -
Gene expression profiling in subcutaneous, visceral, and epigastric adipose tissues of patients with extreme obesity
por: Gerhard, Glenn S., et al.
Publicado: (2013)